Access Barriers Drive Suffering and Higher Costs for C diff Patients

Patients battling C diff are increasingly facing a critical obstacle: access to the most effective treatments. According to a leading patient advocacy voice, the issue is no longer limited to the uninsured or underserved—it is impacting middle- and even upper-income individuals who struggle to obtain optimal care due to insurance policies.

Many payers continue to treat older therapies like vancomycin as the default option, despite newer treatments offering significantly lower recurrence rates. As a result, patients are often required to fail initial therapy before gaining approval for more effective alternatives. This “step therapy” approach can lead to repeated infections, escalating health risks, and mounting emotional and financial burdens.

“The number one issue that we’re seeing is access…we’re talking about middle class, working class, sometimes even affluent people who are struggling to get access to the best treatment for C diff,” said PLF’s CEO Christian Lillis.

Earlier this month, the Peggy Lillis Foundation (PLF) had its 2-day event, the annual National C diff Summit and Lobby Day, which took place in Washington DC, on April 13–14, which gathered patients, caregivers, industry, and other stakeholders who came together for education and advocacy.

The Impact of C diff Reoccurrence

The consequences of delayed access extend beyond individual suffering. Each recurrence of C diff increases the likelihood of severe outcomes, including hospitalization, surgery, and even death. Yet insurers frequently require multiple recurrences before covering advanced options such as newer antibiotics or live biotherapeutic therapies.

Lillis also argues that this reactive approach is not only harmful but economically inefficient. While proactive treatment strategies may cost tens of thousands of dollars upfront, they can prevent the cycle of recurrence that drives total medical costs into the hundreds of thousands per patient.

“We’re talking about a system that will spend a quarter of a million dollars to manage a patient through three recurrences… rather than spend $21,000 to stop that cycle early. That’s not a rational coverage decision,” Lillis said.

Beyond the financial implications, the human toll is profound. Recurrent infections can disrupt careers, strain families, and cause lasting psychological harm. Advocates emphasize that improving access to effective treatments is not just a clinical or economic issue, it is a matter of quality of life.

Efforts are now intensifying to push for policy changes that prioritize early, effective intervention. Advocates argue that aligning coverage decisions with both clinical evidence and long-term cost savings could improve outcomes while reducing overall healthcare spending, potentially saving billions annually.